Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Interferon beta-1a, Quantity: 44 microgram/mL
Merck Healthcare Pty Ltd
Interferon beta-1a
Injection, solution
Excipient Ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol
Subcutaneous
12 pre-filled syringes in single-use autoinjectors, 1 pre-filled syringe in single-use autoinjector, 3 pre-filled syringes in single-use autoinjectors
(S4) Prescription Only Medicine
REBIF is indicated for the treatment of: ? Patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. High risk can be inferred from cerebral MRI with 2 or more lesions suggestive of demyelination.,? Ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. REBIF therapy should not be initiated in secondary progressive MS patients who no longer experience relapses.?
Visual Identification: Clear, colourless solution.; Container Type: Syringe; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2010-10-21
Version: A019-0820 Page 1 of 26 Supersedes: A018-0220 AUSTRALIAN PRODUCT INFORMATION REBIF (INTERFERON BETA-1A) 1. NAME OF THE MEDICINE Interferon beta-1a 2. QUALITATIVE AND QUANTITATIVE COMPOSITION REBIF is registered in two strengths of 22 microgram/0.5 mL (6 MIU) and 44 microgram/0.5 mL (12 MIU) of interferon beta-1a (rch) in pre-filled syringes for single dose use (0.5 mL) and in cartridges for multidose use (1.5 mL). There is also a pre-filled syringe presentation which includes a RebiDose® single use autoinjector (0.5 mL). REBIF also contains mannitol, poloxamer, methionine, water for injections and benzyl alcohol. Sodium hydroxide and acetic acid are used for pH adjustment. For the full list of excipients, see Section 6.1 List of excipients 3. PHARMACEUTICAL FORM Solution for injection Clear to opalescent solution, with pH 3.5 to 4.5 and osmolarity 250 to 450 mOsm/L. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS REBIF is indicated for the treatment of: • Patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. High risk can be inferred from cerebral MRI with 2 or more lesions suggestive of demyelination. • Ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. REBIF therapy should not be initiated in secondary progressive MS patients who no longer experience relapses. 4.2. DOSE AND METHOD OF ADMINISTRATION Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis. When first starting treatment with REBIF, it is recommended that the dose be gradually increased in order to allow tachyphylaxis to develop thus reducing the risk of adverse reactions. It is recommended that 20% of the total dose be administered during the first two weeks of therapy, 50% of the total dose be administered in we Read the complete document